Curcumin Maintenance Therapy for Ulcerative Colitis: Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial
- 14 November 2006
- journal article
- research article
- Published by Elsevier BV in Clinical Gastroenterology and Hepatology
- Vol. 4 (12), 1502-1506
- https://doi.org/10.1016/j.cgh.2006.08.008
Abstract
No abstract availableThis publication has 31 references indexed in Scilit:
- Depression and anxiety in people with inflammatory bowel diseaseJournal of Epidemiology and Community Health, 2001
- Role of NF-κB in immune and inflammatory responses in the gutGut, 1998
- Nuclear factor κB is activated in macrophages and epithelial cells of inflamed intestinal mucosaGastroenterology, 1998
- Activation of nuclear factor kappa B in inflammatory bowel diseaseGut, 1998
- Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B.JCI Insight, 1998
- Curcumin inhibits the proliferation and cell cycle progression of human umbilical vein endothelial cellCancer Letters, 1996
- Curcumin induces apoptosis in immortalized NIH 3T3 and malignant cancer cell linesNutrition and Cancer, 1996
- Balsalazide in the maintenance treatment of patients with ulcerative colitis, a double‐blind comparison with sulphasalazineAlimentary Pharmacology & Therapeutics, 1988
- Risk of Ulcerative Colitis among Former and Current Cigarette SmokersNew England Journal of Medicine, 1987
- SulfasalazineDigestive Diseases and Sciences, 1983